Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market.  Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives.  Sales will begin this month.

Commenting on this new contract, Derma Sciences' CEO Ed Quilty stated, "This is a key milestone for us as we continue to build our proprietary wound care franchise.  While we will double our direct sales force in 2010 from 10 to 20 sales representatives, our sales efforts are focused on areas outside of acute care.  With almost 6,000 hospitals in the US, a very large specialty sales force is necessary for optimal penetration into this market.  Medline is a proven leader in acute care, both in traditional and advanced wound care.  The company is a perfect partner to help Derma Sciences maximize BIOGUARD™ sales."  

Along with over 800 sales representatives, this contract will allow Medline to place BIOGUARD™ products on its current traditional wound care Group Purchasing Organization agreements.   It will be a key new product introduction in 2010 for Medline, adding to the company's list of proprietary wound care products in the United States.

Jack Bowser, President of the division within Medline that is responsible for sales of its gauze-based line of products into acute care, stated, "We view the antimicrobial gauze market as an enormous potential for us, and are excited to have negotiated for the rights to BIOGUARD™ in acute care.  After 2008, hospitals are no longer reimbursed for costs associated with treating many infections that are acquired within their facilities.  As such, there is a much greater focus on prevention.  BIOGUARD™, due to the nature of the product, is an ideal gauze-based line of products which can be used throughout hospital systems as a part of their infection control programs."

SOURCE Derma Sciences, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies RNA molecule crucial for skin wound healing